Recro Pharma's lead painkiller succeeds in mid-stage trial

by Reuters
Wednesday, 6 January 2016 12:22 GMT

Jan 6 (Reuters) - Drugmaker Recro Pharma Inc said its lead painkiller was safe and well tolerated in post-operative orthopedic surgery patients in a mid-stage trial.

The injectable drug, Meloxicam, had no serious adverse events, bleeding or reactions, the company said on Wednesday. (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey)

Our Standards: The Thomson Reuters Trust Principles.